title: Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data.
abstract: OBJECTIVE
  The objective of this study was to compare the anatomical and functional outcomes of ranibizumab versus aflibercept for the treatment of macular edema due to central retinal vein occlusion (CRVO) in routine clinical practice.
  
  
  METHODS
  Participants in this observational study included 62 treatment-naïve patients with CRVO who received intravitreal injections of either ranibizumab or aflibercept. The demographic data, best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography (SD-OCT) characteristics were evaluated at baseline and at months 1, 2, 3, 6, 12 and 18 post-treatment.
  
  
  RESULTS
  At month 18, the mean BCVA of ranibizumab-treated eyes increased 7.9 letters, compared to 7.4 letters for eyes receiving aflibercept, with a similar number of injections. There was no statistically significant difference between the two groups in letters or in central subfield thickness at month 18. At the end of the follow-up, 50% of patients in the ranibizumab group and 42.9% in the aflibercept group showed complete resolution of macular edema.
  
  
  CONCLUSIONS
  Ranibizumab and aflibercept demonstrated similar anatomical and functional outcomes over 18-month follow-up in patients with macular edema due to CRVO, with a similar number of injections.
authors.affiliation: 2nd Department of Ophthalmology, Attikon Hospital, University of Athens, 28, Papanastasiou street, Agios Dimitrios, 17342, Athens, Greece. eirchat@yahoo.gr.
authors.forename: Irini
authors.initials: I
authors.lastname: Chatziralli
authors.affiliation: 2nd Department of Ophthalmology, Henry Dunant Hospital, Athens, Greece.
authors.forename: George
authors.initials: G
authors.lastname: Theodossiadis
authors.affiliation: 1st Department of Ophthalmology, University of Athens, Athens, Greece.
authors.forename: Marilita M
authors.initials: MM
authors.lastname: Moschos
authors.affiliation: 2nd Department of Ophthalmology, Ophthalmiatrion Athinon, Athens, Greece.
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Mitropoulos
authors.affiliation: 2nd Department of Ophthalmology, Attikon Hospital, University of Athens, 28, Papanastasiou street, Agios Dimitrios, 17342, Athens, Greece.
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Theodossiadis
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D058449:Intravitreal Injections; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D011446:Prospective Studies; D000069579:Ranibizumab / Q000008:administration & dosage*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000008:administration & dosage* / Q000037:antagonists & inhibitors; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*; D012170:Retinal Vein Occlusion / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D013997:Time Factors; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D011993:Recombinant Fusion Proteins; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab
keywords: Aflibercept; Central subfield thickness; Optical coherence tomography; Ranibizumab; Retinal vein occlusion; Visual acuity